探索2型糖尿病患者对杜拉鲁肽血糖反应的合适标志物：一项回顾性研究

IF 2.8 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes Therapy Pub Date : 2022-03-13 DOI:10.1007/s13300-022-01231-1

S. Yoshiji, Masashi Hasebe, Y. Iwasaki, Kimitaka Shibue, Yamato Keidai, Yohei Seno, Kanako Iwasaki, S. Honjo, Jun Fujikawa, A. Hamasaki

引用次数: 3

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism

自引率

7.90%

发文量

130

期刊介绍： Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.